Hot Pursuit     06-Mar-25
Zydus Lifesciences Ltd spurts 2.11%, up for third straight session
Zydus Lifesciences Ltd is quoting at Rs 906.2, up 2.11% on the day as on 12:49 IST on the NSE. The stock is down 7.22% in last one year as compared to a 0.19% fall in NIFTY and a 6.32% fall in the Nifty Pharma index.

Zydus Lifesciences Ltd rose for a third straight session today. The stock is quoting at Rs 906.2, up 2.11% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.51% on the day, quoting at 22451.5. The Sensex is at 74122.32, up 0.53%. Zydus Lifesciences Ltd has dropped around 8.85% in last one month.

Meanwhile, Nifty Pharma index of which Zydus Lifesciences Ltd is a constituent, has dropped around 7.57% in last one month and is currently quoting at 20126.8, up 1.39% on the day. The volume in the stock stood at 23.98 lakh shares today, compared to the daily average of 11.17 lakh shares in last one month.

The benchmark March futures contract for the stock is quoting at Rs 908.2, up 1.78% on the day. Zydus Lifesciences Ltd is down 7.22% in last one year as compared to a 0.19% fall in NIFTY and a 6.32% fall in the Nifty Pharma index.

The PE of the stock is 20.42 based on TTM earnings ending December 24.

Previous News
  Zydus Life’s Ahmedabad facility gets EIR from USFDA
 ( Hot Pursuit - 01-Oct-24   12:13 )
  Board of Zydus Lifesciences approves acquisition of majority stake in Amplitude Surgical SA, France
 ( Corporate News - 11-Mar-25   14:20 )
  Zydus Lifesciences receives USFDA approval for Scopolamine Transdermal System
 ( Corporate News - 30-Aug-24   15:12 )
  Zydus Life Jarod facility receives USFDA warning letter
 ( Hot Pursuit - 30-Aug-24   15:11 )
  Zydus' transdermal patch manufacturing facility completes USFDA inspection
 ( Corporate News - 01-Oct-24   12:26 )
  Zydus Life’s Maharashtra facility clears USFDA inspection with zero observations
 ( Hot Pursuit - 17-Feb-25   10:02 )
  Zydus Lifesciences' injectable manufacturing site concludes USFDA inspection
 ( Corporate News - 24-Apr-24   09:49 )
  Zydus Lifesciences receives USFDA approval for Ibuprofen and Famotidine tablets, 800 mg/26.6 mg
 ( Corporate News - 22-Feb-25   13:33 )
  Zydus receives USFDA approval for Paliperidone Extended-Release Tablets
 ( Corporate News - 10-Oct-24   16:08 )
  Zydus Life receives USFDA approval for manufacturing Ibuprofen and Famotidine tablets
 ( Hot Pursuit - 24-Feb-25   11:20 )
  Zydus' transdermal manufacturing site completes USFDA inspection
 ( Corporate News - 19-Jul-24   19:26 )
Other Stories
  Kamat Hotels Q4 PAT surges 412% YoY to Rs 11 cr
  26-Apr-25   16:21
  Bank of Maharashtra Q4 PAT climbs 23% YoY to Rs 1,493 crore
  26-Apr-25   15:34
  Oracle Financial Services Software Q4 PAT up 19% QoQ
  26-Apr-25   14:28
  Force Motors Q4 PAT surges 210% YoY to Rs 435 cr; declares dividend of Rs 40/sh
  26-Apr-25   14:02
  L&T Finance Q4 PAT rises 15% YoY to Rs 636 crore
  26-Apr-25   13:31
  RBL Bank PAT drops 81% YoY to Rs 69 crore in Q4 FY25; provisions zoom by 90% YoY
  26-Apr-25   12:12
  Tejas Networks reports dismal Q4 outcome
  26-Apr-25   11:54
  Zydus Life gets 6 observations from USFDA for API plant
  26-Apr-25   11:02
  RIL Q4 PAT rises 6.4% YoY
  26-Apr-25   10:05
  Tata Technologies Q4 PAT climbs 12% QoQ to Rs 189 cr
  25-Apr-25   17:34
Back Top